The U.S.-based Boston Scientific Corp. has admitted there is an increased risk of blood clots caused by use of its drug-coated cardiac stent.
The company -- the leading stent seller in the nation -- says an analysis of clinical data reveals the increased risk of blood clots months after a stent is implanted, The Wall Street Journal reported, noting the announcement marks the first time any stent maker has acknowledged the heightened risk of side effects from using drug-coated stents.
Stents are small, wire-mesh tubes that are inserted into a blood vessel or other body structure to provide support and keep the structure open. The drugs used to coat some stents are designed to prevent growth of tissue after implantation.
The Journal said stent sales exceed $5 billion annually in a market dominated by Boston Scientific and Johnson & Johnson.
Boston Scientific, which has its headquarters in Natick, Mass., claims recent studies suggest both its Taxus brand of stent and J&J's Cypher stent present similar risks of late-occurring blood clots. J&J company officials, however, told the Journal they see no statistically significant risk of late thrombosis caused by their Cypher stents.
Copyright 2006 by United Press International
Related stories:
Tiny 3-D ultrasound probe guides catheter procedures
An ultrasound probe small enough to ride along at the tip of a catheter can provide physicians with clearer real-time images of soft tissue without the risks associated with conventional x-ray catheter guidance.
More aortic chest aneurysms being treated with less-invasive stents
An estimated 60,000 Americans are walking around with time bombs in their chests called thoracic aortic aneurysms. At any time, their main chest artery could suddenly burst open, causing massive internal bleeding that is almost always fatal.
Stent grafts: a better way to treat blunt trauma injuries
Endovascular repair—fixing an injury in a blood vessel from inside that vessel—is a better option for individuals who receive highly lethal injuries from high-speed collisions or falls (together referred to as blunt trauma) and is shown to save more lives and nearly eliminate paraplegia (the loss of the ability to move and/or feel both legs), a complication of surgical repair for thoracic aortic aneurysms.
Still puzzling: Best care for the frail and elderly with coronary artery disease
A new study from Duke University Medical Center finds that patients treated solely with medications after suffering from chest pain, heart attack or coronary artery disease are more likely to die during the first year following their initial hospitalization.
PCI preference -- will that be an arm or a leg?
When it comes to stenting – using metal tubes to prop open blocked arteries – physicians are continuing to choose to gain entry to the circulatory system through an opening in the leg instead of the arm, even though the latter option appears to be safer, with fewer side effects, say researchers at Duke Clinical Research Institute.
Drug-releasing stents linked with decrease in procedures to unblock coronary arteries
The widespread adoption of the use of drug-releasing coronary artery stents into routine practice is associated with a decrease in the need for repeat procedures to unblock coronary arteries and also do not appear to increase the risk of death, compared to bare-metal stents, according to a study in the June 25 issue of
JAMA.
More patients with drug-coated cardiac stents survive, avoid costly follow-up procedures
The more than ten million Americans who’ve received drug-eluting stents to open their blocked coronary arteries have a bright future, according to new research from the University of Pennsylvania School of Medicine.
Landmark study reveals superiority of bivalirudin in heart attack patients at 30 days
The Cardiovascular Research Foundation (CRF) announced today that the New England Journal of Medicine published results of the HORIZONS AMI trial which showed the use of the anticoagulant bivalirudin following angioplasty in heart attack patients reduced net adverse clinical events by 24 percent compared to the standard treatment, as well as reduced the risk of overall mortality by 33 percent and cardiac mortality by 38 percent.